ProKidney reports 2025 net loss $151.6M, cash $270M; Phase 3 PROACT 1 on track for mid-2026 enrollment

PROKIDNEY CORP.

Net loss $151.6M in 2025 vs $163.3M in 2024; no revenue as pre-revenue cell therapy company.
Cash and marketable securities $270.0M at Dec 31, 2025, down from $358.3M; runway into mid-2027.
Phase 3 PROACT 1 enrollment for accelerated approval (n~360) on track for mid-2026; top-line eGFR slope data Q2 2027.
FDA confirmed in July 2025 Type B meeting that eGFR slope can serve as surrogate endpoint for accelerated approval.
Positive Phase 2 REGEN-007 results presented at ASN Kidney Week 2025 and published in CJASN.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROKIDNEY CORP. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

ProKidney Corp. (the "Company") issued a press release to announce its financial results for the year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0001193125-26-113893

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.